Lewis X oligosaccharides-heparanase complex targeting to DCs enhance antitumor response in mice

被引:12
作者
Chen, Hongjie [1 ,2 ]
Yuan, Bangqing [3 ]
Zheng, Zhaocong [1 ]
Liu, Zheng [1 ]
Wang, Shousen [1 ]
机构
[1] Fuzhou Gen Hosp Nanjing Command, Dept Neurosurg, Fuzhou 350025, Fujian, Peoples R China
[2] Fujian Med Univ, Dept Neurosurg, Fuzong Med Coll, Fuzhou 350025, Fujian, Peoples R China
[3] 476th Hosp PLA, Fuzhou 350025, Fujian, Peoples R China
关键词
Lewis X oligosaccharides; Heparanase; DCs; Tumor; DENDRITIC CELLS; MOLECULAR-PROPERTIES; TRANS-INFECTION; IN-VITRO; T-CELLS; SIGN; CANCER; EXPRESSION; ANTIGEN; ANGIOGENESIS;
D O I
10.1016/j.cellimm.2011.03.021
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Heparanase has been proved as an promising tumor antigen for the therapeutical target. However, the antigen alone cannot fully elicit the immune response in vivo. In this study, Lewis X oligosaccharides-heparanase complex was prepared, which can target to the dendritic cells (DCs) via dendritic cell-specific intercellular-adhesion-molecule-grabbing non-integrin (DC-SIGN). In addition, the DCs were loaded with the complex, and then were utilized to immunize mice to detect the immune response. Our data demonstrated that the modified DCs could enhance the specific IFN-gamma production and cytotoxic T cell response. Furthermore, the modified DCs could also significantly suppress the established tumor growth and prolong the life span of tumor-bearing mice. Therefore, the Lewis X oligosaccharides-heparanase complex might be regarded as an ideal vaccine, and represent a novel way for the therapeutical strategy of tumor. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:144 / 148
页数:5
相关论文
共 28 条
[11]   RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: A quantitative analysis [J].
Javorovic, M ;
Pohla, H ;
Frankenberger, B ;
Wölfel, T ;
Schendel, DJ .
MOLECULAR THERAPY, 2005, 12 (04) :734-743
[12]   Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases [J].
Kelly, T ;
Suva, LJ ;
Huang, Y ;
MacLeod, V ;
Miao, HQ ;
Walker, RC ;
Sanderson, RD .
CANCER RESEARCH, 2005, 65 (13) :5778-5784
[13]  
Koliopanos A, 2001, CANCER RES, V61, P4655
[14]   Enhancement of clonogenicity of human multiple myeloma by dendritic cells [J].
Kukreja, Anjli ;
Hutchinson, Aisha ;
Dhodapkar, Kavita ;
Mazumder, Amitabha ;
Vesole, David ;
Angitapalli, Revathi ;
Jagannath, Sundar ;
Dhodapkar, Madhav V. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (08) :1859-1865
[15]   DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection [J].
Kwon, DS ;
Gregorio, G ;
Bitton, N ;
Hendrickson, WA ;
Littman, DR .
IMMUNITY, 2002, 16 (01) :135-144
[16]   Heparanase: a target for drug discovery in cancer and inflammation [J].
McKenzie, E. A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (01) :1-14
[17]   Expression of Heparanase in Renal Cell Carcinomas: Implications for Tumor Invasion and Prognosis [J].
Mikami, Shuji ;
Oya, Mototsugu ;
Shimoda, Masayuki ;
Mizuno, Ryuichi ;
Ishida, Masaru ;
Kosaka, Takeo ;
Mukai, Makio ;
Nakajima, Motowo ;
Okada, Yasunori .
CLINICAL CANCER RESEARCH, 2008, 14 (19) :6055-6061
[18]   DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation [J].
Moris, A ;
Nobile, C ;
Buseyne, F ;
Porrot, F ;
Abastado, JP ;
Schwartz, O .
BLOOD, 2004, 103 (07) :2648-2654
[19]   Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap [J].
Nabekura, T ;
Otsu, M ;
Nagasawa, T ;
Nakauchi, H ;
Onodera, M .
MOLECULAR THERAPY, 2006, 13 (02) :301-309
[20]   Heparanase: a key enzyme involved in cell invasion [J].
Parish, CR ;
Freeman, C ;
Hulett, MD .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1471 (03) :M99-M108